// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Assessing the safety of treatment cessation in Takayasu arteritis

Chanaka Dahanayake - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Takayasu arteritis

N/A

Developing a pathway for tocilizumab treatment in giant cell arteritis: a South London regional experience

Pratyasha Saha - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Giant cell arteritis

Tocilizumab

Patient perceptions of physical activity following a diagnosis of giant cell arteritis: a multinational qualitative study

Keziah Austin - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Giant cell arteritis

N/A

Efficacy and safety of rituximab in the treatment of systemic vasculitis: experience at a single centre

Carl Orr - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Rituximab

Not a headache clinic: giant cell arteritis fast track pathways (GCA-FTP) need not be overwhelming

Luke Spray - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Giant cell arteritis

N/A

Tocilizumab for giant cell arteritis: real world experience in a single UK centre

Gary Reynolds - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Giant cell arteritis

Tocilizumab

Diabetes may confer protection from giant cell arteritis: results from a large inception cohort

Luke Spray - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Giant cell arteritis

N/A

Non-GCA diagnoses from a GCA fast track clinic: a single centre with four years' experience (2016-2019)

Abdul kayani - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Real life experience of tocilizumab for the management of giant cell arteritis in Fife, Scotland

Paul Allcoat - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Giant cell arteritis

Tocilizumab

Crystallising care: improving hospital gout management

Benjamin D Clarke - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Gout

N/A

Experiences of delivering a nurse-led fracture risk assessment for patients with inflammatory rheumatological conditions in primary care

Ashley W Hawarden - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Non-bacterial osteitis syndromes: characterising an adult population

Tiara Gill - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Chronic recurrent multifocal osteomyelitis

N/A

Outcome of blood analysis and spinal radiology secondary marker assessments of osteoporosis (OP) patients seen in the bone health service in a large urban London borough

Rizwan Rajak - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Osteoporosis

Alkaline phosphatase

Predictors of fracture in patients with primary hyperparathyroidism

Demetris Mariannis - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Primary hyperparathyroidism

N/A

Analgesic prescribing in patients with inflammatory arthritis in the NHS

Ian C Scott - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Inflammatory Arthritis

N/A

The lived experiences of cognitive dysfunction in adults with fibromyalgia: a qualitative systematic review

Sandra Derham - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Cognitive dysfunction

N/A

Characterisation of remission in patients with rheumatoid arthritis treated with upadacitinib or comparators

Stephen Hall - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

ABT-494

Anti-inflammatory and immunologic actions of pinolenic acid in rheumatoid arthritis

Rabaa Takala - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Dinoprostone

Monitoring of immunoglobulin levels in RA patients on anti CD20, rituximab

Ceara Rice - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Rituximab

Oral glucocorticoid use is associated with hypertension in patients with RA

Ruth E Costello - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Hypertension

Glucocorticoid

Copyright © 2026. QuantiNova All rights reserved